TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 46)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSION & EXCLUSION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT: VACCINES MARKET
2 RESEARCH METHODOLOGY (Page No. - 51)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES
2.2.2.1 Primary insights
FIGURE 3 KEY INSIGHTS FROM PRIMARY EXPERTS
2.3 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION (INCLUDING COVID-19 VACCINES): VACCINES MARKET, 2022
FIGURE 5 TOTAL REVENUE (INCLUDING COVID-19 VACCINES): VACCINES MARKET
FIGURE 6 REVENUE SHARE OF PFIZER INC., 2022
2.3.1 SEGMENTAL ASSESSMENT
FIGURE 7 TOP-DOWN APPROACH
2.4 GROWTH RATE ASSUMPTIONS
FIGURE 8 CAGR PROJECTION (INCLUDING COVID-19 VACCINES): VACCINES MARKET
FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.5 RESEARCH ASSUMPTIONS
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.7 RISK ASSESSMENT
2.8 IMPACT OF RECESSION IN VACCINES MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY (Page No. - 63)
FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 17 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 18 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 19 VACCINES MARKET, (EXCLUDING COVID-19 VACCINES), BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 20 VACCINES MARKET, (INCLUDING COVID-19 VACCINES), BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 21 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (EXCLUDING COVID-19 VACCINES)
FIGURE 22 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (INCLUDING COVID-19 VACCINES)
4 PREMIUM INSIGHTS (Page No. - 76)
4.1 VACCINES MARKET OVERVIEW (INCLUDING COVID-19 VACCINES)
FIGURE 23 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
4.2 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)
FIGURE 24 RISING PREVALENCE OF CONTAGIOUS DISEASES TO DRIVE MARKET
4.3 NORTH AMERICA: VACCINES MARKET, (EXCLUDING COVID-19 VACCINES) BY TECHNOLOGY AND COUNTRY, 2022
FIGURE 25 CONJUGATE VACCINES AND US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2022
4.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023 VS. 2028
FIGURE 26 CONJUGATE VACCINES TO DOMINATE MARKET IN 2028
4.5 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET (EXCLUDING COVID-19 VACCINES)
FIGURE 27 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 81)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 28 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET
TABLE 4 IMPACT ANALYSIS: VACCINES MARKET
5.2.1 DRIVERS
5.2.1.1 Strong emphasis on launch of novel vaccines
5.2.1.2 Rising prevalence of infectious diseases
FIGURE 29 INCIDENCE OF TUBERCULOSIS IN US, 2017–2021
5.2.1.3 Increasing number of immunization programs
5.2.1.4 Advancements in vaccine technology
5.2.1.5 Robust government support and funding for vaccine development
TABLE 5 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION)
5.2.2 RESTRAINTS
5.2.2.1 High cost of vaccine development
5.2.3 OPPORTUNITIES
5.2.3.1 Increased focus on therapeutic vaccines
5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory processes
5.2.4.2 Frequent product recalls
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 30 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
TABLE 6 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES
TABLE 7 AVERAGE SELLING PRICE OF ADULT VACCINES
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE
TABLE 8 AVERAGE SELLING PRICE OF CONJUGATE VACCINES
TABLE 9 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES
TABLE 10 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES
TABLE 11 AVERAGE SELLING PRICE OF LIVE ATTENUTAED VACCINES
TABLE 12 AVERAGE SELLING PRICE OF TOXOID VACCINES
TABLE 13 AVERAGE SELLING PRICE OF M-RNA VACCINES
5.4.3 AVERAGE SELLING PRICE TREND
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 31 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE
5.7 PIPELINE ANALYSIS
FIGURE 32 CLINICAL TRIALS IN VACCINES MARKET
FIGURE 33 VACCINES MARKET IN CLINICAL TRIALS, BY DISEASE INDICATION
TABLE 14 PIPELINE PRODUCTS UNDER PHASE-2 AND PHASE-3 CLINICAL TRIALS
5.7.1 KEY PIPELINE PRODUCTS
TABLE 15 KEY PIPELINE VACCINES: GSK PL
TABLE 16 KEY PIPELINE VACCINES: MERCK & CO., INC.
TABLE 17 KEY PIPELINE VACCINES: PFIZER, INC.
TABLE 18 KEY PIPELINE VACCINES: SANOFI S.A.
5.8 ECOSYSTEM MARKET/MAP
FIGURE 34 ECOSYSTEM MARKET/MAP
TABLE 19 ROLE IN ECOSYSTEM: VACCINES MARKET
5.9 REGULATORY ANALYSIS
5.9.1 REGULATORY LANDSCAPE FOR VACCINES
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 26 PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 INTENSITY OF COMPETITIVE RIVALRY
5.11 PATENT ANALYSIS
FIGURE 35 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013–SEPTEMBER 2023
TABLE 27 INDICATIVE LIST OF PATENTS IN VACCINES MARKET
5.12 KEY CONFERENCES & EVENTS
TABLE 28 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
5.13.2 KEY BUYING CRITERIA
FIGURE 37 KEY BUYING CRITERIA FOR END USERS IN VACCINES MARKET
6 VACCINES MARKET, BY TECHNOLOGY (Page No. - 114)
6.1 INTRODUCTION
TABLE 29 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD BILLION)
TABLE 30 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD BILLION)
6.2 CONJUGATE VACCINES
6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET
TABLE 31 VACCINES MARKET FOR CONJUGATE VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 33 EUROPE: VACCINES MARKET FOR CONJUGATE VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 34 ASIA PACIFIC: VACCINES MARKET FOR CONJUGATE VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 35 LATIN AMERICA: VACCINES MARKET FOR CONJUGATE VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
6.3 RECOMBINANT VACCINES
6.3.1 LESSER POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET
TABLE 36 EXAMPLES OF RECOMBINANT VACCINES
TABLE 37 VACCINES MARKET FOR RECOMBINANT VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 39 EUROPE: VACCINES MARKET FOR RECOMBINANT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 40 ASIA PACIFIC: VACCINES MARKET FOR RECOMBINANT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 41 LATIN AMERICA: VACCINES MARKET FOR RECOMBINANT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
6.4 INACTIVATED & SUBUNIT VACCINES
6.4.1 EASE OF STORAGE AND TRANSPORTATION TO DRIVE MARKET
TABLE 42 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
TABLE 43 VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 44 NORTH AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES, (EXCLUDING COVID-19 VACCINES) BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 45 EUROPE: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 46 ASIA PACIFIC: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 47 LATIN AMERICA: VACCINES MARKET FOR INACTIVATED & SUBUNIT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
6.5 LIVE ATTENUATED VACCINES
6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO LIMIT MARKET
TABLE 48 EXAMPLES OF LIVE ATTENUATED VACCINES
TABLE 49 VACCINES MARKET FOR LIVE ATTENUATED VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 50 NORTH AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 51 EUROPE: VACCINES MARKET FOR LIVE ATTENUATED VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 52 ASIA PACIFIC: VACCINES MARKET FOR LIVE ATTENUATED VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 53 LATIN AMERICA: VACCINES MARKET FOR LIVE ATTENUATED VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
6.6 TOXOID VACCINES
6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET
TABLE 54 EXAMPLES OF TOXOID VACCINES
TABLE 55 VACCINES MARKET FOR TOXOID VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 56 NORTH AMERICA: VACCINES MARKET FOR TOXOID VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 57 EUROPE: VACCINES MARKET FOR TOXOID VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 58 ASIA PACIFIC: VACCINES MARKET FOR TOXOID VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 59 LATIN AMERICA: VACCINES MARKET FOR TOXOID VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
6.7 VIRAL VECTOR VACCINES
6.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
TABLE 60 VACCINES MARKET FOR VIRAL VECTOR VACCINES (INCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 61 NORTH AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES (INCLUDING COVID-19 VACCINES),, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 62 EUROPE: VACCINES MARKET FOR VIRAL VECTOR VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 63 ASIA PACIFIC: VACCINES MARKET FOR VIRAL VECTOR VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 64 LATIN AMERICA: VACCINES MARKET FOR VIRAL VECTOR VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
6.8 M-RNA VACCINES
6.8.1 INCREASING FOCUS ON M-RNA VACCINE DEVELOPMENT TO DRIVE MARKET
TABLE 65 VACCINES MARKET FOR M-RNA VACCINES (INCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 66 NORTH AMERICA: VACCINES MARKET FOR M-RNA VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 67 EUROPE: VACCINES MARKET FOR M-RNA VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 68 ASIA PACIFIC: VACCINES MARKET FOR M-RNA VACCINES, (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 69 LATIN AMERICA: VACCINES MARKET FOR M-RNA VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
6.9 OTHER VACCINES
TABLE 70 VACCINES MARKET FOR OTHER VACCINES (INCLUDING COVID-19 VACCINES), BY REGION,2021–2028 (USD BILLION)
TABLE 71 NORTH AMERICA: VACCINES MARKET FOR OTHER VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 72 EUROPE: VACCINES MARKET FOR OTHER VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 73 ASIA PACIFIC: VACCINES MARKET FOR OTHER VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 74 LATIN AMERICA: VACCINES MARKET FOR OTHER VACCINES (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
7 VACCINES MARKET, BY TYPE (Page No. - 145)
7.1 INTRODUCTION
TABLE 75 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
7.2 MULTIVALENT VACCINES
7.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
TABLE 77 EXAMPLES OF MULTIVALENT VACCINES
TABLE 78 VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
7.3 MONOVALENT VACCINES
7.3.1 INCREASING INVESTMENT IN R&D AND RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 83 EXAMPLES OF MONOVALENT VACCINES
TABLE 84 VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
8 VACCINES MARKET, BY DISEASE INDICATION (Page No. - 156)
8.1 INTRODUCTION
TABLE 89 VACCINES MARKET, BY DISEASE INDICATION (INCLUDING COVID-19 VACCINES), 2021–2028 (USD MILLION)
TABLE 90 VACCINES MARKET, BY DISEASE INDICATION (EXCLUDING COVID-19 VACCINES), 2021–2028 (USD MILLION)
8.2 PNEUMOCOCCAL DISEASE
8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
TABLE 91 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
TABLE 92 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 93 NORTH AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 95 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 96 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.3 INFLUENZA
8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
TABLE 97 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
TABLE 98 VACCINES MARKET FOR INFLUENZA (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 99 NORTH AMERICA: VACCINES MARKET FOR INFLUENZA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 100 EUROPE: VACCINES MARKET FOR INFLUENZA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 101 ASIA PACIFIC: VACCINES MARKET FOR INFLUENZA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 102 LATIN AMERICA: VACCINES MARKET FOR INFLUENZA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.4 COMBINATION VACCINES
8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET
TABLE 103 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
TABLE 104 VACCINES MARKET FOR COMBINATION VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 105 NORTH AMERICA: VACCINES MARKET FOR COMBINATION VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 EUROPE: VACCINES MARKET FOR COMBINATION VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 107 ASIA PACIFIC: VACCINES MARKET FOR COMBINATION VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 108 LATIN AMERICA: VACCINES MARKET FOR COMBINATION VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.5 HPV
8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET
TABLE 109 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
TABLE 110 VACCINES MARKET FOR HPV (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 111 NORTH AMERICA: VACCINES MARKET FOR HPV (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 113 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 114 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES),, BY COUNTRY, 2021–2028 (USD BILLION)
8.6 MENINGOCOCCAL DISEASE
8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET
TABLE 115 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
TABLE 116 VACCINES MARKET FOR MENINGOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 117 NORTH AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 EUROPE: VACCINES MARKET FOR MENINGOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 119 ASIA PACIFIC: VACCINES MARKET FOR MENINGOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 120 LATIN AMERICA: VACCINES MARKET FOR MENINGOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.7 HERPES ZOSTER
8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
TABLE 121 VACCINES MARKET FOR HERPES ZOSTER (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 122 NORTH AMERICA: VACCINES MARKET FOR HERPES ZOSTER (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 123 EUROPE: VACCINES MARKET FOR HERPES ZOSTER (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 124 ASIA PACIFIC: VACCINES MARKET FOR HERPES ZOSTER (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 125 LATIN AMERICA: VACCINES MARKET FOR HERPES ZOSTER (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.8 ROTAVIRUS
8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO DRIVE MARKET
TABLE 126 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
TABLE 127 VACCINES MARKET FOR ROTAVIRUS (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 128 NORTH AMERICA: VACCINES MARKET FOR ROTAVIRUS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 129 EUROPE: VACCINES MARKET FOR ROTAVIRUS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 130 ASIA PACIFIC: VACCINES MARKET FOR ROTAVIRUS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 131 LATIN AMERICA: VACCINES MARKET FOR ROTAVIRUS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.9 MMR
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO DRIVE MARKET
TABLE 132 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
TABLE 133 VACCINES MARKET FOR MMR (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 134 NORTH AMERICA: VACCINES MARKET FOR MMR (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 135 EUROPE: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 136 ASIA PACIFIC: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 137 LATIN AMERICA: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.1 VARICELLA
8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE MARKET
TABLE 138 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
TABLE 139 VACCINES MARKET FOR VARICELLA (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 140 NORTH AMERICA: VACCINES MARKET FOR VARICELLA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 141 EUROPE: VACCINES MARKET FOR VARICELLA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 142 ASIA PACIFIC: VACCINES MARKET FOR VARICELLA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 143 LATIN AMERICA: VACCINES MARKET FOR VARICELLA (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.11 HEPATITIS
8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
TABLE 144 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
TABLE 145 VACCINES MARKET FOR HEPATITIS (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 146 NORTH AMERICA: VACCINES MARKET FOR HEPATITIS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 147 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), FOR HEPATITIS, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 148 ASIA PACIFIC: VACCINES MARKET FOR HEPATITIS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 149 LATIN AMERICA: VACCINES MARKET FOR HEPATITIS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.12 DTP
8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET
TABLE 150 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
TABLE 151 VACCINES MARKET FOR DTP (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 152 NORTH AMERICA: VACCINES MARKET FOR DTP (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 EUROPE: VACCINES MARKET FOR DTP (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 154 ASIA PACIFIC: VACCINES MARKET FOR DTP (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 155 LATIN AMERICA: VACCINES MARKET FOR DTP (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.13 POLIO
8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
TABLE 156 VACCINES MARKET FOR POLIO (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 157 NORTH AMERICA: VACCINES MARKET FOR POLIO (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 158 EUROPE: VACCINES MARKET FOR POLIO (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 159 ASIA PACIFIC: VACCINES MARKET FOR POLIO (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 160 LATIN AMERICA: VACCINES MARKET FOR POLIO (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
8.14 OTHER DISEASE INDICATIONS
FIGURE 38 NUMBER OF COVID-19 CASES IN US, 2020–2023
TABLE 161 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
TABLE 162 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD BILLION)
TABLE 163 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 164 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 165 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 166 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 208)
9.1 INTRODUCTION
TABLE 167 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), 2021–2028 (USD MILLION)
TABLE 168 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (INCLUDING COVID-19 VACCINES), 2021–2028 (USD MILLION)
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
9.2.1 EASIER ABSORPTION INTO BLOODSTREAM AND BETTER IMMUNE RESPONSE TO DRIVE MARKET
TABLE 169 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
TABLE 170 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 171 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 172 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 174 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
9.3 ORAL ADMINISTRATION
9.3.1 EASE OF ADMINISTRATION AND REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE MARKET
TABLE 175 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 176 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 177 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
9.4 OTHER ROUTES OF ADMINISTRATION
TABLE 180 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 181 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 182 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 183 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 184 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
10 VACCINES MARKET, BY END USER (Page No. - 221)
10.1 INTRODUCTION
TABLE 185 VACCINES MARKET, BY END USER (EXCLUDING COVID-19 VACCINES), 2021–2028 (USD MILLION)
TABLE 186 VACCINES MARKET, BY END USER (INCLUDING COVID-19 VACCINES), 2021–2028 (USD MILLION)
10.2 ADULT VACCINES
10.2.1 ADULT VACCINES SEGMENT TO COMMAND LARGER MARKET SHARE DURING FORECAST PERIOD
TABLE 187 VACCINES MARKET FOR ADULT VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 188 NORTH AMERICA: VACCINES MARKET FOR ADULT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 189 EUROPE: VACCINES MARKET FOR ADULT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 190 ASIA PACIFIC: VACCINES MARKET FOR ADULT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 191 LATIN AMERICA: VACCINES MARKET FOR ADULT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
10.3 PEDIATRIC VACCINES
10.3.1 INCREASED INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET
TABLE 192 VACCINES MARKET FOR PEDIATRIC VACCINES (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 193 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 194 EUROPE: VACCINES MARKET FOR PEDIATRIC VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 195 ASIA PACIFIC: VACCINES MARKET FOR PEDIATRIC VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 196 LATIN AMERICA: VACCINES MARKET FOR PEDIATRIC VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD BILLION)
11 VACCINES MARKET, BY REGION (Page No. - 231)
11.1 INTRODUCTION
TABLE 197 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
TABLE 198 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 39 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
TABLE 199 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 200 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 201 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 203 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 204 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.3 NORTH AMERICA: RECESSION IMPACT
11.3.1 US
11.3.1.1 US to dominate North American vaccines market during forecast period
TABLE 205 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 206 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 207 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 208 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 209 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.3.2 CANADA
11.3.2.1 High incidence of infectious diseases to drive market
TABLE 210 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 211 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 212 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 213 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 214 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.4 EUROPE
TABLE 215 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 216 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 217 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 219 EUROPE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 220 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.5 EUROPE: RECESSION IMPACT
11.5.1 GERMANY
11.5.1.1 Significant R&D investments and growing biotechnology industry to drive market
TABLE 221 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 222 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 224 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.5.2 UK
11.5.2.1 Launch of new products and increased funding by government and non-government organizations to drive market
TABLE 225 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 226 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 227 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 228 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.5.3 FRANCE
11.5.3.1 Favorable government initiatives for mass immunization to drive market
TABLE 229 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 230 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 231 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 232 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.5.4 ITALY
11.5.4.1 Higher investments by companies for increased production capacities to drive market
TABLE 233 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 234 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 235 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 236 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.5.5 SPAIN
11.5.5.1 Rising investments in vaccine development by private organizations to drive market
TABLE 237 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 238 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 240 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.5.6 REST OF EUROPE
TABLE 241 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 242 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 243 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 244 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.6 ASIA PACIFIC
FIGURE 40 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
TABLE 245 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 246 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 247 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 248 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 249 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 250 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.7 ASIA PACIFIC: RECESSION IMPACT
11.7.1 JAPAN
11.7.1.1 Increasing government initiatives for improving quality of vaccines to drive market
TABLE 251 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 252 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 253 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 254 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.7.2 SOUTH KOREA
11.7.2.1 Strong government strategies for improved vaccine hubs to drive market
TABLE 255 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 256 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 257 SOUTH KOREA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD BILLION)
TABLE 258 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.7.3 CHINA
11.7.3.1 Growing investments in biotechnology sector to drive market
TABLE 259 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 260 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 261 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 262 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.7.4 INDIA
11.7.4.1 Increasing government initiatives and development of new and improved vaccines to drive market
TABLE 263 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 264 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 265 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 266 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.7.5 REST OF ASIA PACIFIC
TABLE 267 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 268 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 269 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 270 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.8 LATIN AMERICA
TABLE 271 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 272 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 273 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 275 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 276 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.9 LATIN AMERICA: RECESSION IMPACT
11.9.1 BRAZIL
11.9.1.1 Rising focus on immunization programs by government and non-government bodies to drive market
TABLE 277 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 278 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 280 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.9.2 MEXICO
11.9.2.1 Presence of well-trained health professionals and ethnically varied population base for clinical trials to drive market
TABLE 281 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 282 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 283 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 284 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.9.3 REST OF LATIN AMERICA
TABLE 285 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD BILLION)
TABLE 286 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 287 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 288 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.1 MIDDLE EAST & AFRICA
11.10.1 MIDDLE EAST
11.10.1.1 Increasing prevalence of infectious diseases to drive market
TABLE 289 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 290 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 291 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2021–2028 (USD MILLION)
TABLE 292 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 293 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.10.2 AFRICA
11.10.2.1 Availability of funds and grants from developed economies to drive market
TABLE 294 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 295 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021–2028 (USD MILLION)
TABLE 296 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 297 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2021–2028 (USD MILLION)
11.10.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE (Page No. - 301)
12.1 INTRODUCTION
12.2 KEY STRATEGIES/RIGHT TO WIN
12.3 STRATEGIES OF KEY PLAYERS IN VACCINES MARKET
TABLE 298 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET
12.4 REVENUE SHARE ANALYSIS
FIGURE 41 REVENUE SHARE ANALYSIS, 2020–2022
12.5 MARKET SHARE ANALYSIS
FIGURE 42 MARKET SHARE ANALYSIS OF MAJOR PLAYERS IN VACCINES MARKET, 2022
TABLE 299 DEGREE OF COMPETITION: VACCINES MARKET
12.6 COMPANY EVALUATION MATRIX
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 PARTICIPANTS
FIGURE 43 COMPANY EVALUATION MATRIX, 2022
12.6.5 COMPANY FOOTPRINT
12.6.5.1 Product footprint
12.6.5.2 Regional footprint
12.7 START-UP/SME EVALUATION MATRIX
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
FIGURE 44 START-UP/SME EVALUATION MATRIX, 2022
12.7.5 COMPETITIVE BENCHMARKING
TABLE 300 DETAILED LIST OF KEY START-UPS/SMES
TABLE 301 TECHNOLOGY AND REGIONAL BENCHMARKING FOR START-UPS/SMES
12.8 COMPETITIVE SCENARIOS AND TRENDS
12.8.1 KEY PRODUCT LAUNCHES AND APPROVALS
TABLE 302 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2023
12.8.2 KEY DEALS
TABLE 303 KEY DEALS, JANUARY 2021–SEPTEMBER 2023
12.8.3 OTHER KEY DEVELOPMENTS
TABLE 304 OTHER KEY DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2023
13 COMPANY PROFILES (Page No. - 316)
13.1 KEY PLAYERS
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1.1 PFIZER INC.
TABLE 305 PFIZER INC.: COMPANY OVERVIEW
FIGURE 45 PFIZER INC.: COMPANY SNAPSHOT (2022)
13.1.2 MERCK & CO., INC.
TABLE 306 MERCK & CO., INC.: COMPANY OVERVIEW
FIGURE 46 MERCK & CO. INC.: COMPANY SNAPSHOT (2022)
13.1.3 GSK PLC
TABLE 307 GSK PLC: COMPANY OVERVIEW
FIGURE 47 GSK PLC: COMPANY SNAPSHOT (2022)
13.1.4 SANOFI
TABLE 308 SANOFI: COMPANY OVERVIEW
FIGURE 48 SANOFI: COMPANY SNAPSHOT (2022)
13.1.5 CSL
TABLE 309 CSL: COMPANY OVERVIEW
FIGURE 49 CSL: COMPANY SNAPSHOT (2022)
13.1.6 EMERGENT
TABLE 310 EMERGENT: COMPANY OVERVIEW
FIGURE 50 EMERGENT: COMPANY SNAPSHOT (2022)
13.1.7 JOHNSON & JOHNSON SERVICES, INC.
TABLE 311 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW
FIGURE 51 JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT (2022)
13.1.8 ASTRAZENECA
TABLE 312 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 52 ASTRAZENECA: COMPANY SNAPSHOT (2022)
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
TABLE 313 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW
13.1.10 BAVARIAN NORDIC
TABLE 314 BAVARIAN NORDIC: COMPANY OVERVIEW
FIGURE 53 BAVARIAN NORDIC: COMPANY SNAPSHOT (2022)
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
TABLE 315 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW
13.1.12 DAIICHI SANKYO COMPANY, LIMITED
TABLE 316 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
FIGURE 54 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
13.1.13 PANACEA BIOTEC
TABLE 317 PANACEA BIOTEC: COMPANY OVERVIEW
FIGURE 55 PANACEA BIOTEC: COMPANY SNAPSHOT (2022)
13.1.14 BIOLOGICAL E LIMITED
TABLE 318 BIOLOGICAL E LIMITED: COMPANY OVERVIEW
13.1.15 BHARAT BIOTECH
TABLE 319 BHARAT BIOTECH: COMPANY OVERVIEW
13.1.16 NOVAVAX
TABLE 320 NOVAVAX: COMPANY OVERVIEW
FIGURE 56 NOVAVAX, INC.: COMPANY SNAPSHOT (2022)
13.1.17 INOVIO PHARMACEUTICALS
TABLE 321 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW
FIGURE 57 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 SINOVAC
13.2.2 INCEPTA PHARMACEUTICALS LTD.
13.2.3 VALNEVA SE
13.2.4 VBI VACCINES INC.
13.2.5 BIO FARMA
13.2.6 FSUE NPO MICROGEN
13.2.7 ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
13.2.8 INDIAN IMMUNOLOGICALS LIMITED
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 394)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
Growth opportunities and latent adjacency in Vaccines Market
What are the growing opportunities in Vaccines Market Size, Share, Growth, Covid-19 Impact Analysis, forecasts to 2028 ?
Which are some of the significant growth strategies adopted by leading companies in this market?
According to this report which are the top 3 companies operating in the global vaccine market?
How the Asia Pacific region in the Global Vaccines Market is Expecting a Highest Growth Rate During the Forecast Period?
Which end user segment holds the largest share of the Global Vaccines Market?